Literature DB >> 7647539

[Effect of Epimedium sagittatum on quality of life and cellular immunity in patients of hemodialysis maintenance].

H J Liao1, X M Chen, W G Li.   

Abstract

Our previous study had demonstrated that Chinese medicine Epimedium Sagittatum (ES) exerted immuno-enhancing effect on the animal model of chronic renal insufficiency. In present study, we investigated the therapeutic effect of ES on patients of hemodialysis maintenance. 22 cases of regular hemodialytic patients were treated with ES in the form of decoction. 12 patients with hemodialysis were served as controls. It was found that ES had sexual potentiation effect and improved the quality of life in the patients of chronic renal failure with regular hemodialysis. Interleukin 2 (IL-2) activity of peripheral blood monocytes (PBMC) stimulated by PHA was increased significantly in the patients treated with ES. It was suggested that Chinese medicine ES had therapeutic effect on sexual disorder and immunologic inadequacy in the patients of chronic renal failure undergoing hemodialysis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7647539

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis.

Authors:  Chien-yu Chen; Yea-huey Chang; Da-tian Bau; Hung-jin Huang; Fuu-jen Tsai; Chang-hai Tsai; Calvin Yu-chian Chen
Journal:  Acta Pharmacol Sin       Date:  2009-07-13       Impact factor: 6.150

2.  Establishment of a comprehensive list of candidate antiaging medicinal herb used in korean medicine by text mining of the classical korean medical literature, "dongeuibogam," and preliminary evaluation of the antiaging effects of these herbs.

Authors:  Moo Jin Choi; Byung Tae Choi; Hwa Kyoung Shin; Byung Cheul Shin; Yoo Kyoung Han; Jin Ung Baek
Journal:  Evid Based Complement Alternat Med       Date:  2015-03-10       Impact factor: 2.629

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.